Skip to main content

Table 1 Demographic profile about the selected AD GWAS datasets

From: Mendelian randomization highlights significant difference and genetic heterogeneity in clinically diagnosed Alzheimer’s disease GWAS and self-report proxy phenotype GWAX

Dataset

AD

Control

N

% female

Mean AAO (s.d)

N

% female

Mean AAE (s.d)

GWAS ADGC [9]

14,428

59.3

71.1 (17.3)

14,562

59.3

76.2 (9.9)

GWAS CHARGE [9]

2,137

67.3

82.6 (12)

13,474

55.8

76.7 (8.2)

GWAS EADI [9]

2,240

65

75.4 (9.1)

6631

60.6

78.9 (7.0)

GWAS GERAD [9]

3,177

64

73.0 (0.2)

7277

51.8

51.0 (0.1)

GWAS All [9]

21,982

-

-

41,944

-

-

GWAX 2018 [13]

42,034

65.9

-

272,244

-

-

GWAX 2021 [15]

53,042a

-

-

355,900

-

-

GWAS+GWAX 2018 [13]

67,614

-

-

320,710

-

-

GWAS+GWAX 2019 [14]

71,880

-

-

383,378

-

-

GWAS+GWAX 2021 [15]

75,024

-

-

397,844

-

-

  1. AD Alzheimer’s disease, AAO age at onset, AAE age at examination, s.d standard deviation, GWAS genome-wide association studies, GWAX GWAS by proxy, GWAS+GWAX meta-analyses of GWAS and GWAX
  2. aThese 53,042 AD cases consisted of 898 clinically diagnosed AD and 52,791 AD proxy phenotype